406 results
Page 3 of 21
8-K
ljcf 4667
22 Apr 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:03pm
8-K
EX-99.1
73vulb2oro9
11 Apr 22
Entry into a Material Definitive Agreement
8:03am
424B3
m52qwe8z jj4
27 Dec 21
Prospectus supplement
5:01pm
8-K
EX-99.1
xxlh16of4b7rg
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am
8-K
EX-10.1
1n01ggxev cde2xnq
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
EX-99.1
f8ge e495n
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
EX-4.1
p7th009
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
EX-10.2
b8d1izg0a3mp038pgmre
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
EX-99.1
xf1k1a2mg23oekwi
25 Oct 21
Seelos Therapeutics Presents a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research
2:03pm
8-K
EX-99.2
ehemzegyrscaccv
2 Sep 21
Seelos Therapeutics Announces Senior Management Appointments
4:01pm
8-K
EX-99.1
kczaohh krke2
2 Sep 21
Seelos Therapeutics Announces Senior Management Appointments
4:01pm
8-K
EX-99.1
9v153e6c2 f86dawvg1v
24 May 21
Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
4:15pm
8-K
EX-1.1
wcjnfqdrknl
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
424B5
opzfddckl4kd 9lat
21 May 21
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
c3wj t2uf
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am